Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Chuang, Chia Chang ^a,b   Chuang, Yin Ching ^c   Chang, Wen Teng ^d   Chen, Chi Chung ^c   Hor, Lien I ^a   Huang, A Ming ^a   Choi, Pui Ching ^a   Wang, Chi Yun ^a   Tseng, Po Chin ^a   Lin, Chiou Feng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; [3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER]; ACETIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; ISO 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WORTMANNIN; 3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLEACETIC ACID METHYL ESTER; ISOMERASE; ISOXAZOLE DERIVATIVE; MIF PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; BACTERIUM COLONY; BACTERIUM ISOLATE; BLOOD CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE SEVERITY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; TRANSCRIPTION INITIATION; VIBRIO VULNIFICUS; VIBRIO VULNIFICUS INFECTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PATHOLOGY; SECRETION; VIBRIOSIS; VIROLOGY;

ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-6; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; LEUKOCYTES, MONONUCLEAR; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED BALB C; NF-KAPPA B; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 77957743749     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-50     Document Type: Article

References (32)

1. Tsuchiya T, Mitsuo E, Hayashi N, Hikita Y, Nakao H, Yamamoto S, Miyamoto K, Tsujibo H. Vibrio vulnificus damages macrophage during the early phase of infection. Infect Immun 2007, 75:4592-4596. 10.1128/IAI.00481-07, 1951150, 17591793.
2. Strom MS, Paranjpye RN. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect 2000, 2:177-188. 10.1016/S1286-4579(00)00270-7, 10742690.
3. Hsueh PR, Lin CY, Tang HJ, Lee HC, Liu JW, Liu YC, Chuang YC. Vibrio vulnificus in Taiwan. Emerg Infect Dis 2004, 10:1363-1368.
4. Hor LI, Chang YK, Chang CC, Lei HY, Ou JT. Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol 2000, 44:871-878.
5. Powell JL, Wright AC, Wasserman SS, Hone DM, Morris JG. Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect Immun 1997, 65:3713-3718. 175529, 9284142.
6. Shin SH, Shin DH, Ryu PY, Chung SS, Rhee JH. Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients' sera. FEMS Immunol Med Microbiol 2002, 33:133-138. 10.1111/j.1574-695X.2002.tb00582.x, 12052568.
7. Chiang SR, Tang HJ, Chang PC, Cheng KC, Ko WC, Chen CH, Chuang YC. Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection. J Microbiol Immunol Infect 2007, 40:123-133.
8. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-S35.
9. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002, 4:449-460. 10.1016/S1286-4579(02)01560-5, 11932196.
10. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R. Macrophage migration inhibitory factor sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002, 99:345-350. 10.1073/pnas.012511599, 117563, 11756671.
11. Emonts M, Sweep FCGJ, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, Erard V, Renner P, Hermans PWM, Hazelzet JA, Calandra T. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44:1321-1328. 10.1086/514344, 17443469.
12. Chuang CC, Wang ST, Chen WC, Chen CC, Hor LI, Chuang YC. Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock 2007, 27:503-506. 10.1097/SHK.0b013e31802c024b, 17438455.
13. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. Targeted disruption of macrophage migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999, 189:341-346. 10.1084/jem.189.2.341, 2192995, 9892616.
14. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:64-170.
15. Roger T, Froidevaux C, Martin C, Calandra T. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res 2003, 9:119-123.
16. Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, Lolis E, Al-Abed Y. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 2002, 277:24976-24982. 10.1074/jbc.M203220200, 11997397.
17. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005, 280:36541-36544. 10.1074/jbc.C500243200, 16115897.
18. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-27892. 10.1074/jbc.M703265200, 18056708.
19. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J. Macrophage migration inhibitory factor promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007, 26:5046-5059. 10.1038/sj.onc.1210318, 17310986.
20. O'Sullivan AW, Wang JH, Redmond HP. NF-κB and p38 MAPK inhibition improve survival in endotoxic shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res 2009, 152:46-53. 10.1016/j.jss.2008.04.030, 19027920.
21. Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290:L622-L645. 10.1152/ajplung.00477.2005, 16531564.
22. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJH, Peppelenbosch MP, van der Poll T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002, 168:4070-4077.
23. Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009, 20:353-362. 10.1681/ASN.2008020194, 2637042, 18842989.
24. Chang WT, Huang AM. Pal/NRF-1 regulates the promoter of the human Integrin-associated protein/CD47 Gene. J Biol Chem 2004, 279:14542-14550. 10.1074/jbc.M309825200, 14747477.
25. Tsai CC, Kai JI, Huang WC, Wang CY, Wang Y, Chen CL, Fang YT, Lin YS, Anderson R, Chen SH, Tsao CW, Lin CF. Glycogen synthase kinase-3β facilitates IFN-γ-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol 2009, 183:856-864. 10.4049/jimmunol.0804033, 19542364.
26. Kenzel S, Santos-Sierra S, Deshmukh SD, Moeller I, Ergin B, Fitzgerald KA, Lien E, Akira S, Golenbock DT, Henneke P. Role of p38 and early growth response factor 1 in the macrophage response to group B streptococcus. Infect Immun 2009, 77:2474-2481. 10.1128/IAI.01343-08, 2687355, 19332535.
27. Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K. Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-κB and NF-IL6 in cardiac myocytes. Cardiovasc Res 1999, 42:104-112. 10.1016/S0008-6363(98)00285-5, 10435001.
28. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991, 91:23-29. 10.1016/0002-9343(91)90069-A, 1907101.
29. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992, 215:356-362. 10.1097/00000658-199204000-00009, 1242452, 1558416.
30. Bozza FA, Gomes R, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22:309-313. 10.1097/01.shk.0000140305.01641.c8, 15377884.
31. Lee BC, Kim SH, Choi SH, Kim TS. Induction of interleukin-8 production via nuclear factor-κB activation in human intestinal epithelial cells infected with Vibrio vulnificus. Immunology 2005, 115:506-515. 10.1111/j.1365-2567.2005.02185.x, 1782178, 16011519.
32. West PW, Parker LC, Ward JR, Sabroe I. Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1. Immunology 2008, 125:101-110. 10.1111/j.1365-2567.2008.02825.x, 2526264, 18355244.